- About
- Projects
- Column 1
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
- Food & Nutrition
- Column 2
- Column 1
- News and Events
- Expanded Access eRequest
Trial Design, Treatment Options Spotlighted in Xylazine Conference - MedPageToday
Longer observation periods following treatment and safety considerations for chronic and frequent users are among the many research issues about xylazine-laced fentanyl that need addressing, Rachel Wightman, MD, said at a meeting on mitigating risks from human xylazine exposure sponsored by the Reagan-Udall Foundation.
The FDA’s plan to tackle misinformation - POLITICO Prescription Pulse
FDA Commissioner Robert Califf said Thursday that misinformation, what he sees as one of the biggest issues facing his agency’s many jurisdictions, needs an equally expansive, overlapping approach.
Reagan-Udall Foundation lays out methods for FDA to combat misinformation - Endpoints News
The Reagan-Udall Foundation on Thursday published a wide-ranging report on how the FDA can combat misinformation, marking some progress on one of FDA Commissioner Robert Califf’s key goals for the agency.